Evidence map›Paper›PMID 42032409›Full record

ReviewBulletin of experimental biology and medicine2026

Possible Ways of Reducing Adverse Events Associated with mRNA Vaccines Encapsulated in Lipid Nanoparticles.

L A Kisakova, S A Ilyicheva, A P Rudometov

Abstract readReview
PubMed Publisher
In one paragraph

Review in Bulletin of experimental biology and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

L A KisakovaState Research Center of Virology and Biotechnology "Vector", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia. orlova.lyub1996@yandex.ru.
S A IlyichevaState Research Center of Virology and Biotechnology "Vector", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.
A P RudometovState Research Center of Virology and Biotechnology "Vector", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

mRNA vaccines have a number of advantages over traditional vaccines: high safety (no risk of infection, minimal possibility of integration into the genome), the ability to induce both cellular and humoral immune responses, as well as the possibility of repeated administration due to the absence of antiviral immunity. The effectiveness of Moderna and Pfizer/BioNTech products that use lipid nanoparticles for mRNA delivery have been proven, but they have disadvantages, including the need for ultra-low-temperature storage and side effects associated with lipid components of vaccines. Polymers, polypeptides, dendrimers, and other delivery systems are being investigated as alternative methods of mRNA delivery. This review analyzes the side effects of mRNA vaccines encapsulated in lipid nanoparticles and promising approaches to reducing their reactogenicity.

Indexed as

LipidsmRNA VaccinesNanoparticlesRNA, MessengerAnimalsHumansLiposomesLipid NanoparticlesLipidsLiposomesmRNA VaccinesRNA, Messengerjet injectionlipid nanoparticlesmRNA deliverypostvaccinal adverse eventsRNA vaccines

Identifiers

PMID42032409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.